• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

    10/24/24 4:26:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cuca Roberto

    (Last) (First) (Middle)
    C/O TELA BIO, INC.
    1 GREAT VALLEY PARKWAY, SUITE 24

    (Street)
    MALVERN PA 19355

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    TELA Bio, Inc. [ TELA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    COO and CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    10/24/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/24/2024 P(1) 64,444 A $2.25 155,388(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The shares were purchased in the Issuer's underwritten public offering that closed on October 24, 2024, at the public offering price of $2.25 per share.
    2. Includes 1,079 shares acquired under the Issuer's employee stock purchase plan on July 31, 2024.
    /s/ Megan Smeykal, Attorney-in-fact 10/24/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TELA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Blizard Jeffrey was granted 104,800 shares, increasing direct ownership by 732% to 119,125 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      6/2/25 4:59:08 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Director Evans Douglas G was granted 7,950 shares, increasing direct ownership by 76% to 18,470 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      5/30/25 4:18:35 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Director O'Brien Federica F. was granted 7,950 shares, increasing direct ownership by 76% to 18,470 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      5/30/25 4:18:27 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

      MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. This milestone follows the successful U.S. launch of OviTex Inguinal in 2024, where it has achieved over $1 million in sales in its first year and has seen growing adoption by surgeons seeking a tailored, more natural alternative to synthetic mesh for inguinal hernia procedures. OviTex Inguinal is av

      6/3/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Jeffrey Blizard as President

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

      6/2/25 8:30:00 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference

      MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA's management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the

      5/22/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

      SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      11/14/24 1:06:57 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by TELA Bio Inc.

      SC 13G - TELA Bio, Inc. (0001561921) (Subject)

      10/29/24 5:12:40 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

      SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      10/28/24 4:06:51 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:26:40 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Talmo Paul bought $50,000 worth of shares (22,222 units at $2.25), increasing direct ownership by 32% to 91,082 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:25:59 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Koblish Antony bought $199,998 worth of shares (88,888 units at $2.25), increasing direct ownership by 24% to 458,897 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:25:31 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Leadership Updates

    Live Leadership Updates

    See more
    • TELA Bio Appoints Jeffrey Blizard as President

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

      6/2/25 8:30:00 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Jeffrey Blizard to its Board of Directors

      MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader

      6/4/24 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Greg Firestone as Chief Commercial Officer

      MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group

      5/20/24 4:03:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TELA Bio downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

      3/21/25 8:05:03 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on TELA Bio with a new price target

      Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

      5/31/22 9:13:36 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Financials

    Live finance-specific insights

    See more
    • TELA Bio Reports First Quarter 2025 Financial Results

      MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

      5/8/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio to Announce First Quarter 2025 Financial Results

      MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

      4/17/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

      MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

      3/20/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    SEC Filings

    See more
    • TELA Bio Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TELA Bio, Inc. (0001561921) (Filer)

      6/2/25 8:30:24 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - TELA Bio, Inc. (0001561921) (Filer)

      5/30/25 4:06:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

      SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      5/30/25 4:03:12 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care